Cannabis Science Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, announced that it has commenced production of multiple strains of cannabis and European Union certified hemp varieties to initiate scientific research to select the best strains for development of proprietary formulations for clinical drug development to bring the cannabis formulations to market for critical ailments such as cancer and neurological disorders.
Mario Lap, director and president of European Operations, stated: “Cannabis Science intends to leverage its team’s expertise to create a framework for research and clinical testing. We are excited to report further development and progress as we proceed forward.”
The facilities are located in the Alicante region of Spain, and the Company is working with a local partner to initiate an agricultural program, to prepare GMP production and to start building the research framework to conduct scientific testing of extracts and the active constituents contained in the cannabis plant with the objective of developing selected formulations for clinical use.
Add a Comment